How Assistance Works

Streamlining our patient’s specialty pharmacy experience with unmatched full-service convenience

  • 1. Check Your Coverage/Benefits Verification

    Our team of expert billers finds the best avenues of coverage that minimize out-of-pocket costs.

  • 2. Transfer Prescription to AmeriPharma™

    We process your prescription by working with your previous pharmacy or prescriber, making the transition quick and easy.

  • 3. Prior Authorization

    Our team of specialists obtains approval from your insurance companies within 24 to 72 hours.

  • 4. Copay Assistance & Financial Aid

    We secure financial aid and decrease copays, out-of-pocket expenses, and high deductibles. To date, AmeriPharma™ Specialty Care has secured $55 million in financial assistance for our patients.

  • 5. Nursing Care Coordination

    AmeriPharma™ puts your schedule and home environment first when scheduling and coordinating one of our specialized nurses for your in-home infusions.

  • 6. Delivery Coordination

    Medications are always delivered in strict compliance with the specific requirements for shipping. Next-day and overnight cold-chain deliveries are coordinated around your schedule.

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/block_image.jpg

What Is Jakafi?

Jakafi (ruxolitinib) is a protein kinase inhibitor that inhibits certain enzymes called Janus kinases (JAK), which are involved in the production and growth of red blood cells.

In myelofibrosis (bone marrow cancer) or polycythemia vera (a rare blood disorder), the Janus kinases are overactive, which leads to uncontrolled production of blood cells that can migrate to other organs such as the spleen and cause enlargement. Jakafi inhibits specific signaling pathways and thus stops this overproduction of blood cells.

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/block_image_1.jpg

What Is Jakafi Used For?

  • Myelofibrosis: Jakafi is indicated for the treatment of intermediate or high-risk myelofibrosis (MF). This includes primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults.
  • Polycythemia vera: Jakafi is indicated for the treatment of polycythemia vera (PV) for adults who have experienced an inadequate response to or intolerance of hydroxyurea.
  • Acute graft-versus-host disease: Jakafi is indicated for the treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adults and pediatric patients who are over 12 years of age. 
  • Chronic graft-versus-host disease: Jakafi is indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients (over 12) after failure of one or two lines of systemic therapy.

Duration of Therapy

Your doctor may allow up to 6 months to see if Jakafi works for you. If there is no improvement after 6 months of treatment, your doctor may have you stop taking the medication.

It is important you take Jakafi exactly as prescribed. Do not stop taking it without speaking to your doctor first. The only exception is if you start bleeding. If this happens, stop taking Jakafi and call your doctor immediately.

Copay and Financial Assistance

AmeriPharma™ Specialty Care alleviates financial burdens for patients and their families

  • Advanced software locates funding sources to match you with top-dollar foundation programs

  • One of our copay assistance specialists will assist with the application process

  • Automatic updates will be sent to you and your physician on the status of the funding

https://ameripharmaspecialty.com/wp-content/uploads/2024/05/doctor-patient.jpg

Dosage

Myelofibrosis

The recommended starting dose is based on platelet count:

  • For platelets between 50,000/mm³ and 100,000/mm³ : 5 mg twice daily
  • For platelets between 100,000/mm³ and 200,000/mm³ : 15 mg twice daily
  • For platelets > 200,000/mm³ : 20 mg twice daily

Blood work is done before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.

Doses will be titrated and adjusted by your doctor based on safety, efficacy, and ongoing platelet count.

Polycythemia Vera

For polycythemia vera, the recommended dose is 10 mg twice daily.

Blood work is done before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.

Doses will be titrated and adjusted by your doctor based on safety, efficacy, and ongoing hemoglobin and platelet count.

Acute Graft-Versus-Host Disease

For acute graft-versus-host disease, the recommended dose is 5 mg given orally twice daily.

Blood work is done before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.

Doses will be titrated and adjusted by your doctor based on safety, efficacy, and ongoing absolute neutrophil count (ANC) and bilirubin level.

Chronic Graft-Versus-Host Disease

For chronic graft-versus-host disease, the recommended dose is 10 mg given orally twice daily.

Blood work is done before initiating therapy, every 2 to 4 weeks until doses are stabilized, and then as clinically indicated.

Doses will be titrated and adjusted by your physician based on safety, efficacy, and ongoing ANC and bilirubin level.

Jakafi Side Effects

The most common side effects include:
  • Thrombocytopenia (low platelets)
  • Anemia (low red blood cell counts)
  • Neutropenia (low white blood cell counts)
  • Risk of infection (i.e., tuberculosis, progressive multifocal leukoencephalopathy, herpes zoster, and hepatitis B)
  • Bruising
  • Dizziness
  • Headache
  • Diarrhea

Insurances Accepted

We accept Medicare, multi-state Medicaid, Medi-Cal, Blue Shield, and most private insurances. Call us to find out more about your coverage.

  • Medicaid logo

Get Started in Minutes

Fill out your information and one of our specialists will call you ASAP.

How Much Can You Save?

Speak with a copay assistance specialist

(877) 778-0318